CLINICAL TRIAL: STUDY OF TAMOXIFEN AND RALOXIFENE (STAR) FOR THE PREVENTION OF B

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项对乳腺癌风险增加的绝经后妇女的研究，她们被随机分配到他莫昔芬或雷洛昔芬，以确定哪一种最有效，副作用最少。 一项大型临床试验的证据表明，他莫昔芬有助于降低乳腺癌发病率的妇女谁是在发展的疾病的风险增加。 美国食品和药物管理局（FDA）已批准他莫昔芬用于此类用途。 雷洛昔芬已被FDA和加拿大健康保护分支（HPB）批准用于预防绝经后（停止绝经的女性）的骨质疏松症（骨变薄）。 研究人员认为，雷洛昔芬也可能降低患乳腺癌的风险，而且副作用比他莫昔芬少。 FDA和HPB认为雷洛昔芬用于降低乳腺癌风险的使用目前尚处于实验阶段。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study of postmenopausal women at increased risk for breast cancer who are randomized to either Tamoxifen or Raloxifene to determine which is most effective with the least amount of side effects. Evidence from a large clinical trial shows that tamoxifen helps to reduce the incidence of breast cancer in women who are at increased risk for developing the disease. The U.S. Food and Drug Administration (FDA) has approved tamoxifen for such use. Raloxifene has been approved by the FDA and the Canadian Health Protection Branch (HPB) for the prevention of osteoporosis (thinning of bones) in postmenopausal (women who have stopped menstruating). Researchers think raloxifene may also reduce the risk of developing breast cancer and have fewer side effects than tamoxifen. The FDA and the HPB consider the use of raloxifene for reducing the risk of breast cancer to be experimental at this time.